Journal
CANCER LETTERS
Volume 385, Issue -, Pages 243-250Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2016.10.016
Keywords
Celecoxib; Plumbagin; Synergy; COX-2; STAT3; Tumor development
Categories
Funding
- NIH [R01 CA-136667-02, RO1 CA-1138634-02, RO1 CA-127892-01A]
- Foreman Foundation for Melanoma
- Geltrude Foundation
- Penn State Melanoma and Skin Cancer Center
- J. Roland, Mary R Elizabeth A Gilbert Memorial Trust
- James Paul Sutton Medical Research Fund
- Penn State Chocolate Tour Research Fund
Ask authors/readers for more resources
Melanoma is a highly drug resistant cancer. To circumvent this problem, a class of synergistically acting drug combinations, which inhibit multiple key pathways in melanoma cells, could be used as one approach for long-term treatment of this deadly disease. A screen has been undertaken on cell lines to identify those that could be combined to synergistically kill melanoma cells. Plumbagin and Celecoxib are two agents that were identified to synergistically kill melanoma cells by inhibiting the COX-2 and STAT3 pathways, which are constitutively activated in up to 70% of melanomas. The combination of these two drugs was more effective at killing melanoma cells than normal cells and decreased cellular proliferation as well as induced apoptosis of cultured cells. The drug combination inhibited development of xenograft melanoma tumors by up to 63% without affecting animal weight or blood biomarkers of organ function, suggesting negligible toxicity. Mechanistically, combination of Celecoxib and Plumbagin decreased melanoma cell proliferation and retarded vascular development of tumors mediated by inhibition of COX-2 and STAT3 leading to decreased levels of key cyclins key on which melanoma cell were dependent for survival. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available